Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: Dose response

The Journal of Pediatrics

Volumn 124, Issue 2, 1994, Pages 302-308

  Finer, Neil N ^a   Etches, Philip C ^a   Kamstra, Barbara ^a   Tierney, Anne J ^a   Peliowski, Abraham ^a   Ryan, C Anthony ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLES; BOVINE SURFACTANT; NITRIC OXIDE; SURFACTANT; UNCLASSIFIED DRUG;

AEROSOL; ARTERIAL OXYGEN SATURATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL DIAPHRAGM HERNIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRACORPOREAL OXYGENATION; HUMAN; NEWBORN HYPOXIA; OXYGEN TENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACORPOREAL MEMBRANE OXYGENATION; HERNIA, DIAPHRAGMATIC; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; OXYGEN; PERSISTENT FETAL CIRCULATION SYNDROME; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY INSUFFICIENCY;

EID: 0027976855     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(94)70324-8     Document Type: Article

References (33)

1. Neonatal pulmonary hypertension: pathophysiology, classification, and etiology
2. Persistent pulmonary hypertension in the neonate
3. Neonatal ECMO Registry of the Extracorporeal Life Support Organization (ELSO)
4. Biological actions and properties of endothelium- derived nitric oxide formed and released from artery and vein
5. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
6. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
7. Biotransformation of nitric oxide
8. Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin
9. Inhaled "endothelium-derived relaxing factor" (EDRF) in primary hypertension (PPH) [Abstract]
10. Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation
11. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb
12. Treatment of persistent pulmonary hypertension in the newborn lamb by inhaled nitric oxide
13. Inhaled nitric oxide-a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction
14. Inhaled nitric ocide-a selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep
15. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn
16. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn
17. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide
18. Inhalational nitric oxide therapy for persistent pulmonary hypertension of the newborn
19. Inhaled nitric oxide for the adult respiratory distress syndrome
20. Recommendations for occupational safety and health standards
21. Safety requirement for use of inhaled nitric oxide in neonates
22. Safety guidelines for use of nitric oxide
23. Measurement of nitrogen dioxide formation from nitric oxide by chemiluminescence in ventilated children
24. Surfactant treatment of full-term newborns with respiratory failure
25. Pathophysiology of congenital diaphragmatic hernia III: exogenous surfactant therapy for the high-risk neonate with CDH
26. Pathophysiology of congenital diaphragmatic hernia. II. The fetal lamb CDH model is surfactant deficient
27. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs
28. Efficacy of Exosurf versus bovine surfactant in ECMO candidates [Abstract]
29. Pathophysiology of congenital diaphragmatic hernia (CDH) VIII: inhaled nitric oxide (NO) requires exogenous surfactant therapy (EST) [Abstract]
30. Surfactant deficiency does not alter nitric oxide (NO) vasodilator effects in rabbit lungs [Abstract]
31. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
32. Inhaled nitric oxide in congenital cyanotic heart disease